Among triple-negative breast cancer patients failing to achieve pCR (n = 96), 10.4% (n = 10) showed a conversion from HER2-0 primary breast cancer to HER2-low-positive residual disease and 24.0% (n = 23) showed a switch in the opposite direction. This evidence concerns the gene ERBB2 and breast carcinoma.